These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37118819)

  • 1. Bispecific T cell-engager targeting oncofetal chondroitin sulfate induces complete tumor regression and protective immune memory in mice.
    Skeltved N; Nordmaj MA; Berendtsen NT; Dagil R; Stormer EMR; Al-Nakouzi N; Jiang K; Aicher A; Heeschen C; Gustavsson T; Choudhary S; Gögenur I; Christensen JP; Theander TG; Daugaard M; Salanti A; Nielsen MA
    J Exp Clin Cancer Res; 2023 Apr; 42(1):106. PubMed ID: 37118819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a bispecific immune engager using a recombinant malaria protein.
    Nordmaj MA; Roberts ME; Sachse ES; Dagil R; Andersen AP; Skeltved N; Grunddal KV; Erdoğan SM; Choudhary S; Gustsavsson T; Ørum-Madsen MS; Moskalev I; Tian W; Yang Z; Clausen TM; Theander TG; Daugaard M; Nielsen MA; Salanti A
    Cell Death Dis; 2021 Apr; 12(4):353. PubMed ID: 33824272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
    Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
    BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
    Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.
    Ivasko SM; Anders K; Grunewald L; Launspach M; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Lode HN; Andersch L; Schulte JH; Eggert A; Hundsdoerfer P; Künkele A; Zirngibl F
    Front Immunol; 2022; 13():1023206. PubMed ID: 36700232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
    Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
    J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.
    Clausen TM; Pereira MA; Al Nakouzi N; Oo HZ; Agerbæk MØ; Lee S; Ørum-Madsen MS; Kristensen AR; El-Naggar A; Grandgenett PM; Grem JL; Hollingsworth MA; Holst PJ; Theander T; Sorensen PH; Daugaard M; Salanti A
    Mol Cancer Res; 2016 Dec; 14(12):1288-1299. PubMed ID: 27655130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.
    Benonisson H; Altıntaş I; Sluijter M; Verploegen S; Labrijn AF; Schuurhuis DH; Houtkamp MA; Verbeek JS; Schuurman J; van Hall T
    Mol Cancer Ther; 2019 Feb; 18(2):312-322. PubMed ID: 30381448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro toxicological support to establish specification limit for anti-CD3 monospecific impurity in a bispecific T cell engager drug, ERY974.
    Harada A; Shioda A; Ikuno T; Iwata Y; Shiraiwa H; Wakabayashi T; Sano Y; Mishima M
    Toxicol In Vitro; 2020 Aug; 66():104841. PubMed ID: 32247040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration.
    Agerbaek MØ; Pereira MA; Clausen TM; Pehrson C; Oo HZ; Spliid C; Rich JR; Fung V; Nkrumah F; Neequaye J; Biggar RJ; Reynolds SJ; Tosato G; Pullarkat ST; Ayers LW; Theander TG; Daugaard M; Bhatia K; Nielsen MA; Mbulaiteye SM; Salanti A
    Int J Cancer; 2017 Apr; 140(7):1597-1608. PubMed ID: 27997697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade.
    Xu L; Li B; Pi C; Zhu Z; Tao F; Xie K; Feng Y; Xu X; Yin Y; Gu H; Fang J
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
    Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
    Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
    Xu Y; Fu J; Henderson M; Lee F; Jurcak N; Henn A; Wahl J; Shao Y; Wang J; Lyman M; Funes V; Espinoza B; Zhang R; Washington I; Chen SY; Zlomke H; Wang J; Niu N; Li P; Meng F; Burns W; Friedrich M; Stienen S; Bailis JM; Zheng L
    Gastroenterology; 2023 Nov; 165(5):1219-1232. PubMed ID: 37507075
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Baniel CC; Heinze CM; Hoefges A; Sumiec EG; Hank JA; Carlson PM; Jin WJ; Patel RB; Sriramaneni RN; Gillies SD; Erbe AK; Schwarz CN; Pieper AA; Rakhmilevich AL; Sondel PM; Morris ZS
    Front Immunol; 2020; 11():1610. PubMed ID: 32849544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
    Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
    Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.